Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

BPC-157: Dosage, Benefits, FDA Status & Clinics (2026)

What Is BPC-157? BPC-157 is a 15-amino-acid synthetic peptide derived from a protein sequence found in human gastric juice. Its full name — Body Protection Compound — comes from that origin. Researchers have been studying it since the early 1990s, and the prec

By Recovery & Performance Peptides Editorial Team

What Is BPC-157?

BPC-157 is a 15-amino-acid synthetic peptide derived from a protein sequence found in human gastric juice. Its full name — Body Protection Compound — comes from that origin. Researchers have been studying it since the early 1990s, and the preclinical data on tissue repair, tendon healing, and gut protection is genuinely interesting. The problem is that almost all of it comes from rodent studies. No completed, peer-reviewed human clinical trial has been published.

That gap between preclinical promise and clinical evidence matters a lot, because the FDA has placed BPC-157 in its Category 2 prohibited category, barring compounding pharmacies from including it in any preparation. If you've seen it offered by a telehealth clinic or peptide vendor in the US, that's not a legal gray area — it's a violation of current FDA policy.

Here's what you'll find on this page: an honest breakdown of what the animal research actually shows, what we genuinely don't know about human use, and what the regulatory situation means for you practically.

BPC-157 is a synthetic 15-amino-acid peptide with significant preclinical evidence for tissue repair and gut healing — but no completed human clinical trials.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Frequently Asked Questions About BPC-157 Dosage

Educational BPC-157 discussions usually land around 200 to 500 mcg per day. The exact framework depends on route, cycle length, and how the protocol is being measured. Yes. Injectable, oral, and more localized protocol discussions often use similar nominal ranges on paper, but the planning logic changes because measurement, reconstitution, and research context change with the route. Short educational examples often use 2 weeks, while more common protocol discussions run about 4 to 6 weeks. The useful planning habit is to define the cycle in advance and reassess instead of letting it drift indefinitely. Both schedules are discussed. Some protocols favor a once-daily routine for simplicity, while others split the daily total into two administrations for timing or measurement reasons. Use a calculator once the vial amount, reconstitution volume, and target mcg dose are already known. That is the step that converts a protocol idea into a usable syringe volume and unit marking. Because the pharmacokinetic picture in humans is not well established. In practice, BPC-157 planning usually depends more on route, daily schedule, cycle length, and measurement consistency than on precise half-life assumptions.
02

Question drills

Open a question for its connected answer.

01Frequently Asked Questions About BPC-157+

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.

SOURCE / peptidemind.com ↗
02What If I Don't See Symptom Relief Within the First Week?+

Reassess dosing first. Subtherapeutic doses delay the VEGF upregulation response that drives initial stabilisation. Research models typically use 200–500 mcg/kg; if you're significantly below that range (adjusted for human equivalent dosing), you may not reach the threshold for angiogenic signalling. Second consideration: lesion severity. Transmural ulcers with significant inflammatory burden take longer to stabilise than superficial erosions. If you're 10 days in with zero symptom change, consider whether concurrent factors (ongoing NSAID use, H. pylori infection, high alcohol consumption) are actively counteracting the peptide's protective effects.

SOURCE / realpeptides.co ↗
03What If I Miss a Scheduled BPC-157 Injection Dose?+

Administer the missed dose as soon as you remember if fewer than 6 hours have passed since the scheduled time, then resume your regular twice-daily schedule. If more than 6 hours have elapsed, skip the missed dose entirely. Do not double-dose to compensate. BPC-157's 4-hour half-life means plasma levels drop significantly within 8 hours, but a single missed dose is unlikely to reverse therapeutic gains achieved over prior weeks. Consistency matters more than perfection across a 4–8 week protocol.

SOURCE / realpeptides.co ↗
04What If I Experience Injection-Site Redness or Swelling?+

Local inflammation at the injection site lasting 24–48 hours without fever or spreading redness typically indicates minor tissue irritation from needle trauma or peptide concentration. Not infection. Rotate injection sites daily (abdominal quadrants, lateral thighs) to prevent repeated trauma to the same tissue. If swelling persists beyond 72 hours, spreads beyond the immediate injection area, or is accompanied by warmth and fever, discontinue use and consult a healthcare provider. Those are infection warning signs.

SOURCE / realpeptides.co ↗
05What If I'm Still Taking NSAIDs Daily—Can BPC-157 Work Simultaneously?+

Yes—BPC-157 can promote healing even during continued NSAID exposure, but the rate of repair depends on NSAID dose and frequency. Studies using concurrent administration showed measurable lesion reduction within 48–72 hours despite ongoing COX inhibition. The peptide's angiogenic and collagen synthesis effects operate independently of prostaglandin pathways, so they aren't blocked by NSAIDs the way misoprostol's mechanism would be. However, reducing NSAID dose or switching to selective COX-2 inhibitors (celecoxib) when medically appropriate accelerates healing because it reduces ongoing mucosal injury rate.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Community Research

Join others researching BPC-157 — share findings, ask questions, and learn from real experiences Synthetic peptide derived from gastric juice protein, renowned for tissue repair, inflammation reduction, and GI protection capabilities. BPC-157 promotes blood vessel formation, enhances collagen synthesis, modulates growth factor expression, and protects against tissue damage through localized or systemic delivery. Promotes blood vessel formation (angiogenesis), enhances collagen synthesis, modulates growth factor expression including VEGF, and protects against tissue damage through localized or systemic delivery pathways.

RESEARCH

Vial Sizes and Concentration Planning for BPC-157 Research

BPC-157 is commonly supplied in lyophilized vial sizes of 2 mg, 5 mg, and 10 mg for research use. Selecting the appropriate vial size and planning the reconstitution volume determines the working concentration and, ultimately, the precision of each BPC-157 dosage. Researchers should calculate their target concentration before reconstitution, as adding the wrong volume of bacteriostatic water will result in doses that deviate significantly from the intended BPC-157 dosage. 5 mg (5,000 mcg) 2 mL 2,500 mcg/mL 0.10 mL (10 IU) 5 mL 1,000 mcg/mL 0.25 mL (25 IU) 10 mg (10,000 mcg) 5,000 mcg/mL 0.05 mL (5 IU) 10 mL When planning a BPC-157 dosage protocol, researchers should also account for the stability window of the reconstituted solution. Reconstituted BPC-157 stored in bacteriostatic water at 2–8°C (refrigerator temperature) is generally considered stable for 4–6 weeks. Exposure to light, heat above 25°C, or repeated freeze-thaw cycles can degrade the peptide and reduce the effective BPC-157 dosage per injection below the intended amount. All vials should be stored lyophilized until the date of reconstitution, and each vial should be reconstituted only once for multi-dose use rather than reconstituting partial vials on multiple occasions. For precise dosage calculations tailored to your specific vial size and desired concentration, use our free Peptide Reconstitution Calculator. This tool eliminates manual calculation errors and ensures each BPC-157 dosage in your research protocol is consistent across the full study duration.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

Comparison Table: Dosage Calculation Methodologies

Choosing the right approach to calculate BPC-157 dosage involves weighing several factors. Here's a quick comparison of common methods and their implications: Manual Calculation U…

Comparison

BPC-157 + LL-37 Synergy: Mechanism Comparison

Primary Pathway VEGFR2 upregulation → angiogenesis via PI3K/Akt signalling FPRL1 activation → neutrophil chemotaxis and cytokine modulation via NF-κB BPC-157 establishes vascular …

Continue reading

Related articles